Efficacy News and Research

RSS
Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Long-acting inhaled combination therapy best for COPD

Long-acting inhaled combination therapy best for COPD

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

α1-adrenoceptor blockade improves nocturia and sleep quality

α1-adrenoceptor blockade improves nocturia and sleep quality

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Researchers identify group of cells in brain that plays important role in Down syndrome

Researchers identify group of cells in brain that plays important role in Down syndrome

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

Gene therapy offers potential alternative to pacemakers

Gene therapy offers potential alternative to pacemakers

Ruthigen treats first human subjects with leading drug candidate RUT58-60

Ruthigen treats first human subjects with leading drug candidate RUT58-60

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.